CyFlow™ CD21 Purified
| Alternative Name: | C3dR , CR2, EBV-R |
| Antibody: | Yes |
| Antigen: | CD21 |
| Application: | Flow cytometry, Immunohistochemistry (frozen sections) |
| Clonality: | monoclonal |
| Clone: | LT21 |
| Field of Interest: | Immunophenotyping |
| Format/Fluorochrome: | Purified |
| Isotype: | IgG1 |
| Regulatory Status: | RUO |
| Source Species: | Mouse |
| Target Species: | Cow, Dog, Human, Pig |
| Product number: | BJ686541 |
For Research Use Only
| HLDA Workshop | HLDA VI—WS Code B CD21.1 |
| Concentration Unit | mg/mL |
| Concentration | 1 |
| Quantity | 0.1 mg |
| Volume | 0.1 mL |
| Immunogen | IM9 human B-lymphoblastoid cell line |
| Background Information | CD21 (CR2; complement receptor 2) binds C3 complement fragments, especially its breakdown fragments, which remain covalently attached to complement activating surfaces or antigen. CD21 has important roles in uptake and retention of immunocomplexes, survival of memory B cells and in development and maintenance of the humoral response to T-dependent antigens. CD21 also serves as a key receptor for Epstein-Barr virus binding and is involved in targeting prions to folicular dendritic cells and expediting neuroinvasion following peripheral exposure to prions. A soluble form of the CD21 (sCD21) is shed from the lymphocyte surface and retains its ability to bind respective ligands. |
| Storage Buffer | The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.09% (w/v) sodium azide. |
| Storage | Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze. |
| Stability | Do not use after expiration date stamped on vial label. |
| Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland Publishing Inc, New York. 1997; 1‑1342. < NLM ID: 9712219 > | Kasprzak A, Spachacz R, Wachowiak J, Stefanska K, Zabel M: Epstein‑Barr virus (EBV) infection in B‑cell non‑Hodgkin's lymphomas in children: virus latency and its correlation with CD21 and CD23 molecules. Folia Histochem Cytobiol. 2007; 45(3):169‑79. < PMID: 17951165 > | Filatov AV, Krotov GI, Zgoda VG, Volkov Y: Fluorescent immunoprecipitation analysis of cell surface proteins: a methodology compatible with mass‑spectrometry. J Immunol Methods. 2007 Jan 30; 319(1‑2):21‑33. < PMID: 17098248 > | Twohig J, Kulik L, Haluszczak C, Reuter J, Rossbach A, Bull M, Holers VM, Marchbank KJ: Defective B cell ontogeny and immune response in human complement receptor 2 (CR2, CD21 transgenic mice is partially recovered in the absence of C3. Mol Immunol. 2007 Jul; 44(13):3434‑44. < PMID: 17379312 > | Faldyna M, Samankova P, Leva L, Cerny J, Oujezdska J, Rehakova Z, Sinkora J: Cross‑reactive anti‑human monoclonal antibodies as a tool for B‑cell identification in dogs and pigs. Vet Immunol Immunopathol. 2007 Sep 15; 119(1‑2):56‑62. < PMID: 17673300 > | Roozendaal R, Carroll MC: Complement receptors CD21 and CD35 in humoral immunity. Immunol Rev. 2007 Oct; 219:157‑66. < PMID: 17850488 > | Zabel MD, Heikenwalder M, Prinz M, Arrighi I, Schwarz P, Kranich J, von Teichman A, Haas KM, Zeller N, Tedder TF, Weis JH, Aguzzi A: Stromal complement receptor CD21/35 facilitates lymphoid prion colonization and pathogenesis. J Immunol. 2007 Nov 1; 179(9):6144‑52. < PMID: 17947689 > | Singh A, Blank M, Shoenfeld Y, Illges H: Antiphospholipid syndrome patients display reduced titers of soluble CD21 in their sera irrespective of circulating anti‑beta2‑glycoprotein‑I autoantibodies. Rheumatol Int. 2008 Jan 3; < PMID: 23949624 >